| 2024-12-09 | +0.87 % |
|
| 2024-12-06 | -0.47 % |
|
| 2024-12-05 | +0.45 % |
|
| 2024-12-03 | +0.44 % |
|
| 2024-11-27 | +0.41 % |
|
| 2024-11-26 | -0.88 % |
- Catalent, Inc. (CTLT) stock fell by 0.88% amid a series of changes in investor positions, downgrades from analysts, and disappointing quarterly earnings that missed consensus estimates.
The decline in Catalent's stock is primarily attributed to a recent earnings report that revealed a loss of $0.13 per share, significantly below analysts' expectations, along with downgrades from various analysts regarding its stock rating.
- Catalent (CTLT) stock decreased by 0.88% after Victory Capital Management Inc. reduced its holdings, along with a series of other institutional investors, amid disappointing quarterly earnings results that missed consensus estimates and a shift in analysts' ratings.
- Catalent (CTLT) stock experienced a decline of -0.88% last night, possibly due to investor sentiment favoring competitors like Exelixis over SQZ Biotechnologies, as highlighted in a comparison showing Exelixis’ superior revenue and earnings, as well as stronger institutional ownership and analyst recommendations.
- Catalent (CTLT) stock declined by 0.88% following mixed news about institutional investments, insider selling of shares, and disappointing quarterly earnings that fell short of analysts' expectations.
|
| 2024-11-25 | +0.51 % |
|
| 2024-11-20 | +0.2 % |
|
| 2024-11-19 | +0.17 % |
|
| 2024-11-14 | -0.41 % |
|
| 2024-11-12 | -0.35 % |
|
| 2024-11-08 | -0.85 % |
|
| 2024-11-01 | +0.22 % |
|
| 2024-10-31 | -0.63 % |
|
| 2024-10-25 | -0.69 % |
|
| 2024-10-23 | -0.87 % |
|
| 2024-10-22 | -0.43 % |
|
| 2024-10-21 | -0.18 % |
|
| 2024-10-18 | +0.33 % |
|
| 2024-10-17 | -0.32 % |
|
| 2024-10-16 | -0.63 % |
|
| 2024-10-15 | +0.02 % |
|
| 2024-10-14 | +0.33 % |
|
| 2024-10-11 | -0.43 % |
|
| 2024-10-10 | -0.41 % |
|
| 2024-10-04 | -0.2 % |
|
| 2024-10-03 | +0.43 % |
|
| 2024-10-02 | +0.37 % |
|
| 2024-09-30 | +0.4 % |
|
| 2024-09-27 | +0.07 % |
|
| 2024-09-26 | +0.72 % |
|
| 2024-09-25 | -0.47 % |
|
| 2024-09-24 | +0.65 % |
|
| 2024-09-23 | -0.42 % |
|
| 2024-09-13 | -0.12 % |
|
| 2024-09-11 | -0.2 % |
|
| 2024-09-09 | -0.17 % |
|
| 2024-09-06 | -0.65 % |
|
| 2024-09-05 | -0.53 % |
|
| 2024-08-15 | +0.69 % |
|
| 2024-08-09 | -0.07 % |
|
| 2024-08-07 | -0.07 % |
|
| 2024-07-25 | +0.09 % |
|
| 2024-07-02 | +0.07 % |
|
| 2024-07-01 | -0.12 % |
|
| 2024-06-26 | +0.04 % |
- Summary: Novo Nordisk A/S plans to invest $4.1 billion in a new US factory, boosting its production capacity and leading to a rise in Novo’s stock. This investment is part of a broader trend where pharmaceutical companies like Novo, Eli Lilly, and Catalent are making multi-billion-dollar investments to increase their manufacturing capabilities in response to the growing demand for their drugs in the US market.
Reason for Catalent(CTLT) stock goes up: Catalent's stock could go up as an effect of Novo Nordisk A/S acquiring three of its factories for $11 billion and planning to invest heavily in expanding its production capacity, which can increase business opportunities and partnerships for Catalent, positively impacting its stock value.
- The article discusses American International Group Inc.'s decreased holdings in shares of Catalent, Inc. (CTLT), and various hedge funds modifying their holdings of CTLT, noting that CTLT stock was slightly up, with potential reasons for this increase attributed to market forces, investor sentiment, and recent company developments.
|
| 2024-06-25 | -0.58 % |
|
| 2024-06-24 | -0.05 % |
|
| 2024-06-21 | +3.06 % |
|
